PubRank

Hsing-Pang Hsieh

Author PubWeight™ 64.39‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Synthesis and anti-viral activity of a series of sesquiterpene lactones and analogues in the subgenomic HCV replicon system. Bioorg Med Chem 2005 2.38
2 BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 2004 1.36
3 Aurintricarboxylic acid inhibits influenza virus neuraminidase. Antiviral Res 2008 1.19
4 Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009 1.16
5 Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2009 1.15
6 Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents. J Med Chem 2004 1.08
7 Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother 2004 1.07
8 Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J Med Chem 2002 1.06
9 Shear stress inhibits smooth muscle cell-induced inflammatory gene expression in endothelial cells: role of NF-kappaB. Arterioscler Thromb Vasc Biol 2005 1.01
10 Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers. Mol Cancer 2009 1.01
11 Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. J Med Chem 2006 0.98
12 Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin Ther Pat 2011 0.96
13 Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives. J Med Chem 2010 0.96
14 Identification of BPR3P0128 as an inhibitor of cap-snatching activities of influenza virus. Antimicrob Agents Chemother 2011 0.95
15 Bioassay-guided purification and identification of PPARalpha/gamma agonists from Chlorella sorokiniana. Phytother Res 2008 0.95
16 Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity. J Med Chem 2009 0.95
17 Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold. Bioorg Med Chem Lett 2008 0.91
18 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioavailable dipeptide-derived inhibitor of dipeptidyl peptidase IV. J Med Chem 2006 0.90
19 4- and 5-aroylindoles as novel classes of potent antitubulin agents. J Med Chem 2007 0.88
20 Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer. Expert Opin Investig Drugs 2014 0.87
21 Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity. J Biomed Sci 2010 0.87
22 Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification. J Med Chem 2010 0.87
23 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. J Med Chem 2010 0.86
24 Synthesis and biological evaluation of 1-methyl-2-(3',4',5'-trimethoxybenzoyl)-3-aminoindoles as a new class of antimitotic agents and tubulin inhibitors. J Med Chem 2008 0.86
25 Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts. PLoS One 2012 0.86
26 7-Aroyl-aminoindoline-1-sulfonamides as a novel class of potent antitubulin agents. J Med Chem 2006 0.86
27 Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors. J Med Chem 2008 0.86
28 Synthesis and biological evaluation of 1-(4'-Indolyl and 6'-Quinolinyl) indoles as a new class of potent anticancer agents. Eur J Med Chem 2011 0.85
29 Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biochem Pharmacol 2008 0.85
30 Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities. J Med Chem 2005 0.85
31 Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes. PLoS One 2010 0.85
32 Isocostunolide, a sesquiterpene lactone, induces mitochondrial membrane depolarization and caspase-dependent apoptosis in human melanoma cells. Cancer Lett 2006 0.84
33 Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. FEBS Lett 2004 0.84
34 Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. J Med Chem 2006 0.84
35 Synthesis and evaluation of 3-aroylindoles as anticancer agents: metabolite approach. J Med Chem 2009 0.84
36 Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists. ChemMedChem 2010 0.83
37 Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor. ChemMedChem 2010 0.83
38 Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors. J Med Chem 2013 0.83
39 Design and synthesis of alpha-ketoamides as cathepsin S inhibitors with potential applications against tumor invasion and angiogenesis. J Med Chem 2010 0.83
40 BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses. J Antimicrob Chemother 2010 0.83
41 Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity. J Comput Aided Mol Des 2014 0.83
42 Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075. Anticancer Res 2010 0.82
43 A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors. Anticancer Res 2012 0.81
44 Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency. J Med Chem 2010 0.81
45 Anti-HSV activity of digitoxin and its possible mechanisms. Antiviral Res 2008 0.81
46 Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists. J Med Chem 2009 0.80
47 Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies. J Med Chem 2006 0.80
48 Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. J Med Chem 2009 0.80
49 Advances in Aurora kinase inhibitor patents. Expert Opin Ther Pat 2009 0.80
50 Scaffold-hopping strategy: synthesis and biological evaluation of 5,6-fused bicyclic heteroaromatics to identify orally bioavailable anticancer agents. J Med Chem 2011 0.80
51 Inhibition of HIV-1 Tat-mediated transcription by a coumarin derivative, BPRHIV001, through the Akt pathway. J Virol 2011 0.80
52 BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells. PLoS One 2011 0.80
53 Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules. Proc Natl Acad Sci U S A 2013 0.80
54 Structure-activity relationship studies of 3-aroylindoles as potent antimitotic agents. ChemMedChem 2006 0.79
55 Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors. PLoS One 2013 0.79
56 Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists. J Med Chem 2006 0.79
57 A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells. Anticancer Drugs 2008 0.79
58 Synthesis and structure-activity relationships of 1-benzyl-4,5,6-trimethoxyindoles as a novel class of potent antimitotic agents. ChemMedChem 2009 0.78
59 CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors. Int J Cancer 2014 0.78
60 Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents. J Med Chem 2004 0.78
61 Pronounced induction of endoplasmic reticulum stress and tumor suppression by surfactant-free poly(lactic-co-glycolic acid) nanoparticles via modulation of the PI3K signaling pathway. Int J Nanomedicine 2013 0.78
62 Antiviral drug discovery against SARS-CoV. Curr Med Chem 2006 0.78
63 Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach. ChemMedChem 2014 0.78
64 A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors. Anal Biochem 2008 0.78
65 A novel bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid carcinoma cells. Biochem Pharmacol 2004 0.78
66 A novel aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment. Int J Biol Sci 2013 0.77
67 An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells. PLoS One 2013 0.77
68 3D-QSAR-assisted drug design: identification of a potent quinazoline-based Aurora kinase inhibitor. ChemMedChem 2012 0.77
69 3-[2-((2S)-2-cyano-pyrrolidin-1-yl)-2-oxo-ethylamino]-3-methyl-butyramide analogues as selective DPP-IV inhibitors for the treatment of type-II diabetes. Bioorg Med Chem Lett 2006 0.77
70 Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent. Biochem Pharmacol 2003 0.77
71 Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor. J Med Chem 2013 0.77
72 Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. J Med Chem 2006 0.76
73 Anti-influenza drug discovery: identification of an orally bioavailable quinoline derivative through activity- and property-guided lead optimization. ChemMedChem 2012 0.76
74 First total syntheses of (+/-)-annuionone B and (+/-)-tanarifuranonol. Org Lett 2008 0.75
75 Development and validation of a liquid chromatography-tandem mass spectrometry for the determination of BPR0L075, a novel antimicrotuble agent, in rat plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2006 0.75
76 Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents. J Med Chem 2008 0.75
77 Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes. Drug Metab Dispos 2007 0.75
78 2-amino-3,4,5-trimethoxybenzophenones as potent tubulin polymerization inhibitors. ChemMedChem 2011 0.75
79 Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. J Med Chem 2019 0.75
80 Substituted pyrrolidine-2,4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2006 0.75